ACRS

Aclaris Therapeutics, Inc.

NasdaqAdd to watchlist

Healthcare · Diagnostics & Research

$5.50

+$0.10+1.85%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

1 open-market sale on file ($1.36M), none of them under a pre-arranged plan. Who, and when

Aug 24, 2026$5.50

−$0.81−12.84%over 1M

Session

Day range80% of range

$5.36$5.54

Fundamentals

Visualize fundamentals and more

Market cap: 785.05M
P/E ratio: -

Revenue grew −58.19% in FY2025, +67.06% slower than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AFeb 2026 10-KFeb 2025

added: 64
dropped: 59
re-drafted: 65

Out of 329 passages in this year’s Item 1A.

New this year

Since inception, we have incurred significant net losses. We incurred net losses of $64.9 million and $132.1 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $967.8 million. We …

122 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Data privacy
Reimbursement
Litigation
Export controls
Patent expiry
China
Cybersecurity

And 12 more.

FDA approval
● We rely heavily on third parties for clinical trials, manufacturing, and development support. Their performance impacts our timelines and success.

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

18 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Aclaris Therapeutics, Inc. investor relations

What ACRS has filed with the SEC. This is not Aclaris Therapeutics, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Aclaris Therapeutics, Inc.

Also filed under Diagnostics & Research, ranked by how closely they sit beside ACRS.

TMOThermo Fisher Scientific Inc.compare with ACRS
ILMNILLUMINA, Inc.compare with ACRS
DHR

TWSTTwist Bioscience Corpcompare with ACRS

AAgilent TECHNOLOGIES, Inc.compare with ACRS

ACRS is among the largest companies matching:

gross margin above 70% and still lossmaking

Ask about Aclaris Therapeutics, Inc.

The assistant answers from what ACRS has actually filed: 13 annual reports filed with the SEC, 35 Form 4 filings from the last year and 3 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from ACRS's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Aclaris Therapeutics, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Aclaris Therapeutics, Inc.

Be told the moment a ACRS insider trades
Put Aclaris Therapeutics, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Aclaris Therapeutics, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Aclaris Therapeutics, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Data privacy
Reimbursement
Litigation
Export controls
Patent expiry
China
Cybersecurity

And 12 more.

FDA approval
● We rely heavily on third parties for clinical trials, manufacturing, and development support. Their performance impacts our timelines and success.

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AFeb 2026 10-KFeb 2025

added: 64
dropped: 59
re-drafted: 65

Out of 329 passages in this year’s Item 1A.

New this year

Since inception, we have incurred significant net losses. We incurred net losses of $64.9 million and $132.1 million for the years ended December 31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $967.8 million. We …

122 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add